Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Munich - Delayed Quote EUR

Karyopharm Therapeutics Inc (25K.MU)

Compare
0.5920
0.0000
(0.00%)
At close: February 25 at 9:06:23 AM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
145,237
145,237
146,033
157,074
209,819
Cost of Revenue
6,007
6,007
4,942
5,213
3,402
Gross Profit
139,230
139,230
141,091
151,861
206,417
Operating Expense
258,673
258,673
270,631
294,063
304,688
Operating Income
-119,443
-119,443
-129,540
-142,202
-98,271
Net Non Operating Interest Income Expense
-30,022
-30,022
-12,880
-22,637
-25,464
Other Income Expense
73,100
73,100
-356
-83
-85
Pretax Income
-76,365
-76,365
-142,776
-164,922
-123,820
Tax Provision
57
57
323
369
268
Net Income Common Stockholders
-76,422
-76,422
-143,099
-165,291
-124,088
Diluted NI Available to Com Stockholders
-76,422
-76,422
-143,099
-165,291
-124,088
Basic EPS
-0.63
-0.63
-1.25
-2.02
-1.65
Diluted EPS
-0.93
-0.93
-1.25
-2.02
-1.65
Basic Average Shares
121,863
121,863
114,221
81,871
75,218
Diluted Average Shares
126,809
126,809
114,221
81,871
75,218
Total Operating Income as Reported
-119,443
-119,443
-129,540
-142,202
-98,271
Total Expenses
264,680
264,680
275,573
299,276
308,090
Net Income from Continuing & Discontinued Operation
-76,422
-76,422
-143,099
-165,291
-124,088
Normalized Income
-111,736.5800
-111,736.5800
-143,099
-165,291
-124,088
Interest Income
7,400
7,400
10,943
2,359
582
Interest Expense
37,422
37,422
23,823
24,996
26,046
Net Interest Income
-30,022
-30,022
-12,880
-22,637
-25,464
EBIT
-38,943
-38,943
-118,953
-139,926
-97,774
EBITDA
-38,603
-38,603
-118,423
-139,305
-96,985
Reconciled Cost of Revenue
6,007
6,007
4,942
5,213
3,402
Reconciled Depreciation
340
340
530
621
789
Net Income from Continuing Operation Net Minority Interest
-76,422
-76,422
-143,099
-165,291
-124,088
Total Unusual Items Excluding Goodwill
44,702
44,702
--
--
-110
Total Unusual Items
44,702
44,702
--
--
-110
Normalized EBITDA
-83,305
-83,305
-118,423
-139,305
-96,985
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0003
Tax Effect of Unusual Items
9,387.4200
9,387.4200
--
--
--
12/31/2021 - 7/25/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NKB2.F TG Therapeutics, Inc.
32.37
-3.20%
 
NAMS NewAmsterdam Pharma Company N.V.
21.50
+6.07%
 
TIL Instil Bio, Inc.
17.50
-4.27%
 
ANRO Alto Neuroscience, Inc.
3.1100
-0.96%
 
HUMA Humacyte, Inc.
3.2000
+4.75%